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Abstract Surface ion equilibrium is hypothesized to play
an important role in defining the interactions between
foreign materials and biological systems. In this study, we
compare two surfaces with respect to their ability to acti-
vate adhering platelets. One is a commonly used implant
material TiO2, which binds Ca
2?, and the other one is
glass, which does not. We show, that in the presence of
Ca2?, TiO2 acts as an agonist, activating adhering platelets
and causing the expression on their surface of two well-
known activation markers, CD62P (P-selectin) and CD63.
On the contrary, in the absence of Ca2?, platelets adhering
on TiO2 express only one of the two markers, CD63.
Platelets adhering on glass, as well as platelets challenged
with soluble agonists in solution, express both markers
independently of whether Ca2? is present or not. The
expression of CD62P and CD63 is indicative of the exo-
cytosis of the so-called a- and dense granules, respectively.
It is a normal response of platelets to activation. Differ-
ences in the expression profiles of these two markers point
to differential regulation of the exocytosis of the two kinds
of granules, confirming the recent notion that platelets can
tune their microenvironment in a trigger-specific fashion.
1 Introduction
The interplay between surface physico-chemical properties
of materials and the biological response they elicit is an
active area of research [1]. The role of interfacial ion
equilibrium in this process is an aspect that has not received
sufficient attention despite the recognition of its importance
[1]. In this context, titania–Ca2? interactions represent an
interesting example. Titania (TiO2) is a relatively inert and
stable material responsible for the favorable, if poorly
understood, biocompatibility properties of titanium (Ti),
which is used in the production of various implants—stents,
heart valve housings, dental prostheses and other osseoim-
plants [2–4]. Titania interactions with Ca2? are manifested
in terms of changes of several surface properties, such as the
isoelectric point (IEP, the pH at which proton dissociation
from the surface is balanced by adsorption and the surface
charge is neutralized) and f-potential: the IEP of TiO2 is
shifted in the presence of calcium to higher pH [5–8], and its
f-potential is inverted at a near-physiological Ca2? con-
centration of *3 mM at physiological pH [8]. These
changes can be interpreted in terms of adsorption of Ca2?
ions at the oxide surface; this is the so-called ‘‘chemical’’
interpretation. For a detailed discussion of the chemical
versus physical interpretation of the charge reversal phe-
nomena, the reader is referred to Lyklema et al. [9], while
IEP shifts are discussed in detail in Hunter et al. [10].
In simplest terms, Ca2? adsorption to the surface will
change the balance of interactions between the surface and
the material (proteins, lipids, cells) adsorbing or adhering
to it. Indeed, there is some evidence suggesting that Ca2?
adsorption to titania affects TiO2-protein interactions [11].
Furthermore, on TiO2, Ca
2? elicits a clear response in
terms of lipid behavior in phosphatidyl serine (PS)-con-
taining liposomes and supported lipid bilayers—response
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that is absent on substrates such as silica or glass [12–15].
Interactions of Ca2? with silica are not manifested by the
f-potential reversal [16], and at neutral pH the fraction of
adsorbed Ca2? ions is quite small [17]. For more details,
see Figure S1 in the supporting information. In view of
these observations, we hypothesized that the behavior of
more complex biological systems on TiO2 would also be
affected by the TiO2–Ca
2? interactions. In order to dem-
onstrate that these interactions have an effect on a bio-
logical system, we chose to investigate platelets, because of
a clearly identifiable response in terms of activation, and
their relevance to material biocompatibility.
Platelets are anuclear 3–4 lm cell fragments that circu-
late in the blood, scouring the vascular bed for sites of
injury, where they become activated. Activated platelets
adhere to each other and to the injured tissue, forming a
platelet plug, catalyzing coagulation cascade reactions that
culminate in fibrin production and clot formation, and
coordinate the subsequent inflammatory response and
wound healing processes [18–22]. Platelets achieve these
functions by releasing and expressing on their surface a
variety of soluble and membrane factors—lipids, proteins,
and small molecules—that are stored internally in the qui-
escent platelets. Examples of membrane factors include the
phospholipid phosphatidyl serine (PS), which catalyzes the
assembly of the coagulation cascade proteins [18, 23, 24],
transmembrane protein markers such as CD62P (P-selectin)
and CD63 that are characteristic of the exocytosis of the
a- and dense storage granules, respectively [25], and inte-
grin GPIIb/IIIa, the active form of which is responsible for
the adhesion events [20, 26–31]. Expression of these factors
is a useful measure of platelet activation [20, 32, 33].
Contact with artificial surfaces also activates platelets,
leading to thrombosis [34, 35], which can be successfully
managed with anticoagulants to some extent. However,
complications still arise despite the anticoagulant therapy
[34]. This is a well-known problem for the development of
blood-compatible biomaterials and considerable research
efforts are focused on the discovery and development of
materials with minimal procoagulatory properties [34, 35].
On the other hand, blood coagulation at surfaces of os-
seoimplants is beneficial for implant integration. Because
of its importance, interactions between whole blood, or its
components, and various biomaterials, has been exten-
sively studied [34–40]. Quite a few of these studies focused
specifically on TiO2 [30, 41–51]. There is an overall
understanding of the sequence of events, viz., protein
adsorption—platelet activation—thrombosis, and it is
established that surface protein adsorption and the
dynamics of the protein-adsorbed films play a major role in
the process of platelet activation by foreign materials [34,
42, 52], although direct surface effects have also been
described [26, 41]. However, the nuances of these
processes remain poorly understood; in particular, detailed,
multifactorial studies of platelet activation by surfaces are
hard to come by. There is a distinct lack of suitable bio-
physical models that would allow the principles underlying
these interactions to be elucidated. For this reason, in our
study we focus on the purified platelets and on identifying a
clear cause-and-effect relationship between surface ion
binding and platelet response. We use the expression of
different platelet activation markers to elucidate the effect
of surfaces such as TiO2 and glass on the platelets under
different ionic conditions. We demonstrate that the pattern
of activation marker expression in platelets interacting with
TiO2 depends on whether Ca
2? is present or not. This
effect is absent in platelets adhering on glass as well as in
platelets challenged with agonists in solution.
2 Results
2.1 Platelet Isolation and Purification
Platelets were isolated from human whole blood collected
by venipuncture into sodium citrate anticoagulant. In order
to establish a clear cause-and-effect relationship between
Ca2?–TiO2 interactions and platelet activation at the TiO2
surface, we purified platelets from the plasma proteins.
Purification was done by centrifugation, after Watson
et al. [53] with modifications. Protein concentration in
our samples was *0.05 ± 0.01 mg/ml, compared to
*130 mg/ml in the blood plasma.
Prior to the surface experiments, platelet behavior in
solution was analyzed by flow cytometry to ensure their
purity, minimal activation, and appropriate response to
agonists [53–56]. The results of this analysis are shown
in Fig. 1. They confirm that freshly isolated platelets are
not contaminated by other cells and do not express acti-
vation markers such as CD62P, CD63, active form of
GPIIb/IIIa, or phosphatidyl serine (PS). CD62P and CD63
are indicative of the exocytosis of a- and dense granules,
respectively, that occurs in response to activation [25].
GPIIb/IIIa is a constitutively expressed platelet surface
integrin that changes conformation upon activation, and the
procoagulant phospholipid PS was already discussed above
[18, 20, 23–25, 53–56]. Stimulation with soluble agonists
(PMA or TRAP) lead to the expression of these markers
(Fig. 1, Figure S2 in the Supporting Information). Con-
sistent with previous findings, CD62P and CD63 expres-
sion did not depend on the presence of the extracellular
Ca2? [56–58]. GPIIb/IIIa activation and the detection of
exposed PS with annexin A5 require extracellular Ca2?
(Fig. 1) [54, 59]. Only platelets that were not activated
upon isolation but responded to the agonists as shown in
Fig. 1 were used in subsequent experiments.
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2.2 Expression of the Activation Marker CD62P
Depends on the Extracellular Ca2? in Platelets
Adhering on TiO2, but not on Glass
Freshly isolated, purified platelets were allowed to interact
with freshly cleaned, bare glass surfaces or with TiO2-
coated glass surfaces in a Ca2?-free buffer. They adhered
and spread on both surfaces (Fig. 2). Both the numbers of
adhering platelets and the degree of their spreading were
similar on glass and on TiO2. In both cases, more platelets
adhered after 3 h than after 10 min. Some of the platelets
adhering on TiO2 after 3 h were not spread (Fig. 2a-v and
Figure S3 in the Supporting Information). The numbers of
adhering platelets and their degree of spreading are shown
in Table S3 and Figure S3 in the Supporting Information.
On glass, adhering platelets expressed CD62P and CD63
markers, signalling their activation (Fig. 2a-i, iv, b-i, iii).
Activation was already noted in many of the platelets
incubated with glass for 10 min (Fig. 2a-i, b-i), when
platelets were well-separated. Incubation for 3 h led to a
Fig. 1 Flow cytometry analysis of purified platelets. Platelets
isolated from sodium citrate-anticoagulated blood were re-suspended
in a nominally Ca2?-free buffer and analyzed by flow cytometry
[33, 53, 55, 56, 82, 83]. Results of one representative experiment are
shown as percentages of positive events out of a total of 10,000 events
are shown on the plots. Average values from several experiments are
shown in Figure S2 in the Supporting Information. a The scatter
profile shows one population of cells, 95 % of which stained positive
for the platelet-specific marker CD41a (platelet transmembrane
glycoprotein GPIIb). This is consistent with what is expected of
isolated quiescent platelets that are free of contaminants such as
erythrocytes and white blood cells [56, 82, 83]. Platelets stain positive
for CD62P (b) and CD63 (c) upon addition of 70 lM TRAP (green
and pink histograms) but negative in its absence (orange and
turquoise histograms). Expression of CD62P and CD63 in TRAP-
activated platelets is independent of the extracellular Ca2?: the pink
(absence of Ca2?) and the green (presence of Ca2?) histograms nearly
overlap; this is consistent with previous findings [56, 57]. Isotype
controls are negative in the presence and in the absence of TRAP
(light purple and grey). Sample auto-fluorescence recorded in the
absence of antibodies is shown in black. d Platelets expose PS upon
activation with 70 lM TRAP as judged by the binding of APC-
labeled annexin A5 in the presence of extracellular calcium (green
histogram). Platelets that were not activated with TRAP do not
expose PS (turquoise histogram) even when Ca2? is present (orange
histogram). Annexin A5 binding is Ca2?-dependent; therefore, it is
not possible to check whether PS is expressed on the surface of
TRAP-activated platelets in the absence of Ca2? with this reagent.
Black sample auto-fluorescence in the absence of APC-annexin A5.
e Platelets activated with 10 lM PMA express the active form of
GPIIb/IIIa, as judged by the binding of PAC1 antibody in the
presence of Ca2? (green histogram) [54, 82]. No binding is detected
in platelets that were not activated by PMA (orange and turquoise
histogram). The inactive-to-active conformation change in GPIIb/IIIa
is Ca2?-dependent. The Ca2? requirement for PAC1 antibody binding
is well-established in the literature and was not tested in our
experiments [53, 83, 86]. Isotype controls are negative in the presence
and in the absence of PMA (light purple and grey)
b
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near-confluent layer of activated platelets on the surface
(Fig. 2a-iv). These observations are consistent with previ-
ous reports of platelet activation on glass in the absence of
anticoagulants, both in the presence and in the absence of
plasma proteins [60–63].
Crucially, platelets incubated for 10 min on TiO2 in a
Ca-free buffer did not express CD62P (Fig. 2a-ii) or
respond to TRAP (Fig. 2a-iii). Addition of Ca2? after
adhesion did not activate these platelets and did not restore
their ability to respond to TRAP (Figure S4 in the
Fig. 2 Platelet activation profiles on titania and glass in the calcium-
free buffer. Platelets were incubated with TiO2-coated or bare glass
cover slips for 10 min or for 3 h in a nominally Ca-free buffer and
extensively washed with the same buffer. Platelets that remained on
the surface were incubated with the following antibodies and
observed in the confocal microscope: a anti-CD41a (green) and
anti-CD62P (a-granule marker; red); b anti-CD41a (green) and with
anti-CD63 (dense granule marker; red). a Platelets incubated on glass
stain positive with both CD41a and CD62P, showing clear evidence
of activation after 10 min (i) and after 3 h (iv). Platelets incubated on
TiO2 show no evidence of activation (no staining with CD62P) after
10 min even in the presence of TRAP (ii, iii). Platelets incubated on
TiO2 for 3 h do show evidence of activation (v, vi), however, the co-
localization analysis [vii; white circles in (v) and (vi)] shows that it is
the second (non-spread) population of platelets that expresses CD62P.
The spread platelets from the first layer do not express CD62P even
after 3 h of incubation on TiO2 and in the presence of TRAP (vi).
b CD63 is expressed on platelets adhering to either surface after
10 min or 3 h
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Supporting Information). After 3 h of incubation in a
Ca-free buffer, there were platelets on TiO2 that did
express CD62P and responded to TRAP, but these were the
non-spread platelets (Fig. 2a-v–vii).
Platelets adhering on TiO2 in the absence of Ca
2? did
express the dense granule marker CD63 (Fig. 2b), sug-
gesting that the exocytosis of the a-granules and dense
granules is differentially regulated.
In the presence of 2 mM Ca2?, platelets adhered,
spread, and expressed CD62P both on TiO2 and on glass,
after 10 min and after 3 h (Fig. 3a). More platelets adhered
to the surface in the presence of Ca2? than in its absence
(c.f. Figs. 2a-i, ii and 3a-i, ii; see Table S3 in the Sup-
porting Information), and after 10 min of incubation,
platelets adhering in the presence of Ca2? spread to a
greater extent on both surfaces (Figure S3 in the Support-
ing Information). Furthermore, there was a difference in
the distribution of the integrin GPIIb/IIIa. It appeared to be
concentrated at the periphery of the spread platelets in
presence of Ca2? (Fig. 3a), while it was uniformly dis-
tributed in its absence (Fig. 2). The significance of this
difference is not clear. Such non-uniform staining has been
previously observed with this protein in activated platelets
[64], though platelets adhering on glass are reported to
have a centrally located pool of GPIIb/IIIa surrounded by
concentric rings [20].
2.3 Chelating Intracellular Ca2? Affects
the Expression of Both Activation Markers
(CD62P and CD63)
To further elucidate the role of calcium in the differential
platelet activation at surfaces, the platelet cytoplasmic
calcium was chelated by incubating them with BAPTA-
AM. BAPTA-AM is an ester that can freely cross the
plasma membrane but is hydrolyzed once inside the
platelet. The resulting membrane-impermeable acid acts as
a chelator of cytoplasmic Ca2? [65, 66]. Figure 3b shows
that platelets in solution loose their ability to express
CD62P and CD63 in response to stimulation with TRAP if
their cytoplasmic calcium is chelated by BAPTA-AM. This
is expected, because both processes require the rise in
cytosolic Ca2? [20]. Similarly, chelation of intracellular
Ca2? significantly reduced the ability of platelets adhering
on glass to express these two markers (c.f. Figs. 3c-i, iii,
with Fig. 2a-i, iv for CD62P and Fig. 3c-v, vii with
Fig. 2b-i, iii for CD63). BAPTA-AM treatment also sig-
nificantly reduced the extent of expression of CD63 in
platelets interacting with TiO2 (c.f. Figs. 3c-vi, viii with
Fig. 2b-ii, iv). Since CD62P is not expressed in platelets
interacting with TiO2 in the absence of extracellular Ca
2?,
BAPTA-AM treatment had no further effect on the
expression of this marker (Fig. 3c-ii, iv). Chelation of
intracellular Ca2? did reduce the extent of platelet
spreading on TiO2 and to a lesser extent on glass (Figure
S3 in Supporting Information). A similar effect has previ-
ously been observed on polystyrene [67].
3 Discussion
In the presence of the extracellular calcium, TiO2 acts as an
agonist, activating adhering platelets, as judged by the
expression of the a- and dense granule markers CD62P and
CD63. Its effect is similar to that of glass or of soluble
agonists such as TRAP. In the absence of the extracellular
calcium, the effect of TiO2 on the adhering platelets is
markedly different from that of the other agonists: platelets
adhering on TiO2 express CD63 but not CD62P, while
platelets adhering on glass, or challenged with agonists in
solution, express both markers. These trends are visible in
the images of individual experiments shown in Figs. 2 and
3, and are also apparent in the average data from different
experiments shown in Fig. 4.
The simplest mechanism behind this effect would be that
TiO2, because of its affinity for Ca
2? [5–8], acts as a Ca2?-
chelator: it could deplete intracellular Ca2?, the way
BAPTA-AM does, and/or remove structurally important
ions from the outer surface of the platelet membranes, the
way EDTA does [83]. This mechanism does not account for
our observations, however: firstly, we see a clear difference
between the effect of the intracellular Ca2? chelator BAP-
TA-AM and the effect of TiO2. The former affects the
expression of both markers, while the latter concerns only
CD62P. Secondly, chelation of the extracellular Ca2? by
EDTA or citrate does not prevent the expression of either of
the two markers in platelets challenged with various ago-
nists [68, 69]. In other words, platelets must directly sense
differences in the surface properties between TiO2 in the
presence and in the absence of Ca2?.
It should be pointed out that we observed two kinds of
platelets on both surfaces. We refer to them as spread and
non-spread. The spread platelets are present after 10 min
and have extensive platelet-surface contacts but limited
platelet–platelet contacts (Fig. 2a i, ii). They persist on the
surface after 3 h. The non-spread platelets appear at longer
times and are observed after 3 h (Fig. 2a iv–vii). They have
limited contact with the substrate but appear to be in
contact with other platelets. Most likely, these two popu-
lations arise simply due to the surface exclusion effects: at
the initial stages of adsorption, there is sufficient space for
the adhering platelets to spread, but as the surface becomes
covered, the adsorbing platelets can no longer spread out as
they are limited by the presence of other platelets. There is
a difference in the behavior of the two populations on TiO2
in the absence of Ca2?: the non-spread platelets expressed
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some CD62P and responded to TRAP, while the spread
platelets did not (Fig. 2a-v, vi). This observation may
appear counterintuitive, because platelet spreading and
activation are usually coupled [20, 70, 71]. This is not
always the case, however: non-spread, activated platelets
have been observed before. In platelets adhering on col-
lagen, they appear in the very early stages of the adhesion
process and contribute to thrombus formation through
platelet–platelet interactions [31]. Broberg et al. [72] shows
several examples where platelet spreading and activation
(as judged by the expression of CD62P) are not correlated.
Similarly Pandey et al. [73] show that low concentrations
of lysophosphatidic acid induce platelet shape changes but
not granule secretion. The difference in behavior between
the spread and non-spread platelets we observe on TiO2 in
the absence of Ca2? appears to be related to the platelet-
surface contact area or to the platelet–platelet interactions.
One of the consequences of platelets’ ability to sense
differences in TiO2 surface properties is the differential
expression of the a- and dense granule markers that we
observe on titania in the absence of Ca2?. As early as 1988,
Kang et al. [39] showed that exocytosis of the dense gran-
ules, as judged by the serotonin release, correlated with the
number of platelets adhering to the surface, while the release
of a-granules, as judged by the release of b-thromboglobu-
lin, was selective in regards to the surface properties and
peaked in a particular range of surface wetability values they
tested. Rhodes et al. [37] in 1994 also showed that granule
release was differentially induced by the different surfaces
and flow regimes, and Taylor et al. [74] demonstrated that
the level of expression of a- and dense granule markers
depends on the agonist concentration and strength differ-
ently. These studies were done with whole blood and PrP.
Our observation of the differential granule release is there-
fore not restricted to the purified platelets but is a manifes-
tation of a more general aspect of platelet behaviour, that
could allow them to tune the microenvironment at the wound
site [19]. Molecular mechanism behind this behavior is most
likely rooted in the different regulatory machinery associ-
ated with the secretion of the two types of granules: it is
reported that the secretion of a- and dense granules is reg-
ulated by two different Rab-GTPases (Rab4A and Rab27A)
[75–78] and is affected differently by actin polymerization
inhibitors [57, 77]. a-granules themselves appear to contain
subpopulations, the release of which is regulated differen-
tially [79], further supporting the idea of platelets tuning the
environment of the wound. This is an active area of research
[19]. However, it is at this point not clear how this differ-
ential regulation is achieved: what are the stimuli and how
are they transmitted to the different granules. This compli-
cates further interpretation of our observations at the
molecular level, but does provide an interesting starting
point for further investigations. In the context of the possible
applications, surface-induced and surface-charge regulated
differential granule release can be used for controlled mol-
ecule release from platelets, e.g., by nanoparticles, or
implants in drug delivery applications [80].
4 Materials and Methods
4.1 Blood Collection
Blood collection was organized by the Biobanco Vasco
para la Investigacio´n (Basque Biobank for Research, Gal-
dakao, Spain) and performed with informed consent
according to the appropriate legal and ethical guidelines.
Donors were healthy volunteers without the history of
exposure to medication (such as aspirin) or exposure to
alcohol in the 2 weeks prior to collection. 10 ml of blood
was collected by venipuncture with a 21 gauge needle into
sodium citrate anticoagulant (two 5 ml glass Vacutainer
tubes, Becton Dickenson, Madrid, Spain, from each donor)
and stored at 37 C. First 2 ml of blood was discarded
during the collection to avoid platelet activation by residual
thrombin [53].
Fig. 3 Extracellular versus intracellular Ca2? in platelet activation
on TiO2 and on glass. a Platelets isolated in the calcium-containing
buffer (2 mM CaCl2) were incubated with bare (i and iii) or TiO2-
coated (ii and iv) glass cover slips for 10 min (i and ii) and 3 h (iii and
iv), followed by extensive washing with the same buffer and
incubation with antibodies specific against the platelet marker
CD41a (green) and activation marker CD62P (P-selectin, red). The
expression of P-selectin was observed on the majority of platelets
both after 10 min and 3 h of contact with either surface. b Histograms
Platelets isolated in the nominally calcium-free buffer were treated
with BAPTA-AM (100 lM) for 30 min to chelate the intracellular
Ca2?, and analyzed by flow cytometry. They do not express CD62P
(left, red) or CD63 (right, red) upon stimulation with an agonist
(TRAP). Untreated stimulated platelets do (pink). Non-stimulated
platelets do not express CD62P or CD63 independently of the
BAPTA-AM treatment (green and turquoise). Sample auto-fluores-
cence recorded in the absence of antibodies is shown in black. Plot:
% of CD62P (blue)- and % of CD63 (red)- positive platelets as
determined with flow cytometry by analyzing the histograms such as
those shown on the left upon stimulation with 70 lM TRAP as a
function of the BAPTA-AM concentration. Each point represents an
average of six experiments, three of which were performed in the
Ca-free HEPES buffer and three—in the citrate buffer; no differences
were detected between the two sets. This plot demonstrates that the
chelation of intracellular Ca2? affects the expression of both of these
markers in the same way. c BAPTA-AM treated platelets were
incubated with the glass and TiO2 surfaces and analyzed for CD41a
(green) and CD62P or CD63 (red) expression by confocal micros-
copy. No spreading was observed on either of the two surfaces after
10 min or after 3 h of incubation (see Figure S3 in Supporting
Information). Some CD62P expression is evident in platelets incu-
bated on glass (i and iii). On the contrary, no CD62P expression was
observed in platelets incubated on TiO2 (ii and iv). Some CD63
expression is evident on both glass (v and vii) and TiO2 (vi and viii)
surfaces
b
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4.2 Platelet Preparation [53, 81]
All procedures involving dispensing, pipetting, and trans-
ferring blood were carried out in a sterile laminar flow
cabinet (Faster Two 30, Faster, Italy) to avoid contamina-
tion. Glass- and plasticware was autoclaved before use
unless it was already sterile when purchased. Citrate-anti-
coagulated whole blood was transferred from the
Fig. 4 Summary of the platelet activation profiles under different
conditions employed in this study. Shown in this figure is the
background-subtracted fluorescence intensity, [(S - B)/B], where S is
signal and B is background, in the red channel, corresponding to the
expression of the activation markers CD62P or CD63 under different
conditions used in this study. For each condition, the data was
collected from at least three experiments using the blood of three
different donors. The trends confirm those apparent in the individual
images shown in Figs. 2 and 3. Note the change in scale: while in a–c,
the fluorescence intensity is plotted on a scale from 0 to 100 %, in
d and e it is plotted on the scale from 0 to 1 %, because the average
intensity is so low under these conditions. a Expression of CD62P in
platelets adhering on TiO2 and on glass in the absence of Ca
2?.
Significant levels of CD62P expression are seen on glass. On the other
hand the expression is not detectable on TiO2 after 10 min. After 3 h,
the spread platelets do not express CD62P on TiO2, while the non-
spread platelets do express some. b Expression of CD62P in platelets
adhering on TiO2 and on glass in the presence of Ca
2?. CD62P is
expressed on platelets adhering on both surfaces after 10 min and
after 3 h. c Platelets express CD63 in the absence of Ca2? on both
surfaces. d, e Chelation of intracellular Ca2? by BAPTA-AM affects
the expression of both activation markers. Note the change in scale
compared to a–c
Page 8 of 12 Biointerphases (2012) 7:28
123
Vacutainers to 1.5 ml Eppendorf Safe-lock microcentrifuge
tubes (Sigma Aldrich, Madrid). Platelet count was deter-
mined with a ABX Micros 60 hematology analyzer (Horiba
ABX Diagnostics, Madrid, Spain) and was typically in the
range 1.5–2.5 9 108 platelets per ml. Platelet-rich plasma
was prepared from whole blood by centrifugation at
600 rpm (379g) for 20 min at 37 C in a 5417R Eppendorf
centrifuge (Hamburg, Germany) equipped with a fixed
angle rotor. At this point, platelet and other cell counts were
measured with the hematology analyzer. Red and white
blood cell counts were below 0.01 9 106 and below
0.1 9 106 cells per ml, respectively, platelet counts were on
the order of 2.8 9 108 cells per ml.
PRP layers were collected into a 15 ml falcon tube and
acid-citrate-dextrose (ACD; Sigma, Madrid, Spain) was
added to the PRP in a ratio 1:6 by volume. Platelets were
incubated for 10 min at 37 C and then centrifuged at
7009g at 22 C for 20 min (Sigma 3K30 centrifuge, Fisher
Scientific, fixed angle rotor). The pellet was re-suspended
in citrate buffer (100 mM NaCl, 5 mM KCl, 5 mM Glu-
cose, 1 mM MgCl2, 15 mM citrate, pH 6.5) and centri-
fuged again at 7009g at 22 C for 10 min. The pellet was
finally suspended in the HEPES isolation buffer (145 mM
NaCl, 5 mM Glucose, 1 mM MgCl2, 10 mM HEPES,
5 mM KCl, pH 7.4). For experiments to be carried out in
the presence of extracellular calcium, the pellet was re-
suspended in the HEPES isolation buffer containing 2 mM
calcium. Platelet concentration was adjusted to *1 9 108
cells per ml. Platelet purity was ascertained by flow
cytometry (described below) and was found to be above
99 %.
Protein concentration in the purified platelets was
measured with an ND-1000 Nanodrop spectrophotometer
system (Wilmington, DE, USA) using an extinction coef-
ficient of *1 ml g-1 cm-1.
Platelet isolation was performed within *12 h of blood
collection. All experiments were completed within 24 h of
blood collection. Each experiment was carried out at least
three times with blood from three different donors.
4.3 Platelet analysis by flow cytometry
[33, 53, 56, 82, 83]
Flow cytometry was performed on freshly isolated platelets
to analyze their purity, basal activity, and response to
agonists, with a FACScalibur Flow cytometer (Becton–
Dickinson, Madrid, Spain). 50 ll of the washed platelets
were mixed with 50 ll of HEPES calcium-free buffer or
with 2 mM calcium buffer, as required. For stimulating
platelets, either TRAP (Thrombin receptor activating pep-
tide, Sigma-Aldrich, Madrid, Spain) at a final concentration
of 70 lM, or PMA (Phorbyl methyl acetate, Sigma-
Aldrich, Madrid, Spain), at a final concentration of 10 lM,
were added to the samples. Platelets were identified by
staining samples with PerCPCy5.5-conjugated anti-CD41a
antibody. Activation was evaluated by staining them with
PE-conjugated anti-CD62P (P-selectin), PE-conjugated
anti-CD63, FITC-conjugated PAC1 (antibody against the
active conformation of GPIIb/IIIa) and APC-conjugated
Annexin A5 (staining agent for phosphatidyl serine, PS), in
separate tubes. All the fluorescently labeled reagents used
in the flow cytometry experiments were purchased from
Becton–Dickinson, Madrid, Spain. Samples were incubated
for 30 min at 37 C without agitation before being diluted
with 2 ml of the respective buffer and analyzed by flow
cytometry. Isotype-matched controls were run in parallel to
all monoclonal antibodies. Light scatter and fluorescence
data from 10,000 events were collected with all the
detectors in the logarithmic mode. Antibody binding was
expressed as percentage of platelets positive for an anti-
body using Flow Jo software (Tree Star Inc, Oregon, USA).
4.4 Surface Preparation and Cleaning
Surfaces used in this study were either bare 25 mm #1
microscope coverslip glass slides (Menzel-Gla¨ser, Braun-
schweig, Germany), or the same glass slides coated with
*20 nm layer of TiO2 by magnetron reactive sputtering.
The coating was done in a Leybold dc-magnetron Z600
sputtering unit at the Paul Scherrer Institut (Villigen,
Switzerland) according to the previously published proto-
col [84].
Immediately prior to each experiment, surfaces were
cleaned in 2 % SDS solution that was filtered through
0.2 lm pore diameter syringe filter for 30 min, washed
under a stream of Nano-pure water (Nanopure DiamondTM,
Barnstead International, USA), dried with a stream of fil-
tered nitrogen gas (99.999, AirLiquide Spain, Derio,
Spain), and further cleaned for 30 min in a UV-Ozone
cleaner (BioForce Nanosciences, USA) that was pre-heated
for 30 min immediately prior to this step. This procedure
results in minimal carbon contamination of the surface
(\10 %) as judged by XPS (SAGE HR100, Specs, Berlin,
Germany). No other impurities were detected on the sur-
faces cleaned in this way. This cleaning procedure has been
used by several groups for a wide variety of biophysical
studies [8, 14, 15, 85].
4.5 Platelet Adhesion and Activation Studies
on Glass and TiO2 Surfaces
Platelet adhesion experiments were started no later than 2 h
after platelet preparation. The entire experiment was per-
formed at 37 C.
Freshly cleaned surfaces were mounted in home-made,
500 ll hollow Teflon cells using dental glue. 250 ll of the
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buffer required for the experiment was added to the cell
immediately after the glue had set (*2 min) to reduce as
much as possible the chances of contaminating the surface,
followed by 250 ll of the washed platelets in the same
buffer, and incubated either for 10 min or for 3 h.
After the incubation, the samples were washed by add-
ing and withdrawing 250 ll of the buffer 209 to remove
any non-adhered platelets. Care was taken not to touch the
surface with the pipette tip, not to introduce bubbles, and
not to dry the sample out.
Washed samples were incubated with 5 ll of Per-
CPCy5.5 anti-CD41a antibody and with PE anti-CD62P or
PE anti-CD63 antibody for 30 min and analyzed using
confocal microscope (see below).
For experiments involving platelet stimulation with an
agonist, the above steps were followed by the addition of
TRAP to the sample cell, incubation for 30 min, and
confocal microscopy analysis. For experiments involving
intracellular calcium chelation with BAPTA-AM, platelets
were isolated in calcium free buffer and incubated in the
presence the desired BAPTA-AM concentration (1, 2, 5, 8,
10, 100 lM) for 30 min before they were treated with an
agonist (TRAP) in solution or allowed to interact with the
surfaces. The results of solution experiments are shown in
Fig. 3b, and the results of the surface experiments are
shown in Fig. 3c.
4.6 Confocal Microscopy and Image Analysis
Fluorescence images were obtained using an LSM 510
confocal laser scanning microscope (Carl Zeiss, Jena,
Germany) equipped with Plan-Apochromat 639/1.40 NA
oil immersion objective. All experiments were carried out
in a temperature controlled stage at 37 C. PerCP Cy5.5 and
PE fluorescence was excited with the 488 nm line of the Ar
laser and detected with an avalanche photodiode and a
photomultiplier with LP 655 and BP575-615IR filters,
respectively. 143 9 143 lm2 512 9 512 or 2,048 9 2,048
pixel images were recorded and analyzed using the Zen
(Carl Zeiss, Jena, Germany) or ImageJ version 1.42 soft-
ware to extract the numbers and sizes of the adhering
platelets as well as to highlight the different types of
platelets observed on the surface. The image analysis pro-
cedure was as follows. First, the multi-channel images were
split into separate channels—one corresponding to the anti-
CD41a fluorescence and one corresponding to the CD62P or
CD63 fluorescence. Second, a Gaussian blur filter was
applied to both sets of images to highlight platelet edges.
The numbers of adhering platelets were quantified using
the ImageJ cell counter plugin. Platelets adhering on the
surfaces for 3 h were counted manually because cells were
overlapping and it was difficult to separate them. The
numbers of adhering platelets are quoted in Table S3.
Platelet areas were measured manually by drawing
regions of interest around the platelets using the free hand
drawing tool. Based on the analysis of 180 cells, radii were
calculated to determine the size distribution of the platelets,
adhered on the surface for different experiment conditions.
Due to the aggregation of platelets after 3 h, the exact
number and size of adhered platelets were difficult to
quantify. The results of these analyses under different
experimental conditions are shown in Figure S3.
Two methods were used to determine which of the
adhering platelets were activated:
Method I: First, blurred images for the CD41a and
CD62P or CD63 channel were false colored green and red
respectively. Co-localization was visualized in the merged
images in terms of the appearance of the yellow color.
These images are shown in Figs. 2 and 3 in and Figure S4
in the Supporting Information.
Method II: Background subtraction with rolling ball
radius 50 was used to separate the fluorescence coming
from the spread and the non-spread platelets in each
channel (see white circles in Fig. 2a). The resulting back-
ground-subtracted images were thresholded, leading to
binary images. Logical AND operation was used in the
binary images from each channel to obtain the outline
image shown in Fig. 2a-vii. In such an image, the co-
localization of the two dyes (anti-CD41a and anti-CD62P,
green and red channels, respectively), appears as a double
boundary, signaling activated platelets. Non-activated
platelets appear as single boundaries.
Interestingly, it was the non-spread platelets that were
activated, as shown by both methods. See Sects. 2 and 3 for
further explanation.
To calculate the background subtracted average fluo-
rescence intensities shown in Fig. 4, individual cells were
selected in ImageJ and median intensity within the selected
region in the red channel was calculated. Median intensi-
ties for regions where there were no cells were measured as
well. The intensity for each cell in a given image was than
normalized by the background intensity I = [(I(cell) -
I(background)]/I(background). These normalized intensi-
ties were averaged over the cells observed in different
experiments performed under nominally the same experi-
mental conditions but with blood taken from different
donors. The results are plotted in Fig. 4.
4.7 Cell Viability Analysis [86]
Membrane integrity in platelets adhering on the bare glass
and TiO2-coated glass surfaces was measured by Calcein-
AM stain. This marker is retained in the cytoplasm and
degraded by esterases, unless the cell membrane is dam-
aged. After the adhesion of cells on the surface for 10 min
and 3 h, they were washed, and then 200 ll of 2 mM
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Calcein-AM solution was added to the surface. After
staining for 30 min at 37 C, labeled cells were visualized
using confocal microscope. This analysis showed that
adhesion to the surface did not affect the integrity of the
platelet membranes.
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